经导管介入治疗婴幼儿大型动脉导管未闭临床疗效

目的 探讨应用导管介入治疗直径≥5 mm婴幼儿大型动脉导管未闭(patent ductus arteriosus,PDA)的临床疗效.方法 回顾性分析60例大型PDA(直径≥5 mm)患儿的临床资料,着重分析手术方法、临床疗效和随访结果.结果 56例PDA采用Amplatzer或国产先健动脉导管封堵器,3例采用膜部室间隔缺损封堵器,1例采用肌部室间隔缺损封堵器.封堵成功率为98.3%(59/60),术后1 d超声心动图显示15%(9/60)微量至少量残余分流,术后3月超声心动图复查未见残余分流;3例采用室间隔缺损封堵器患儿术后12月超声心动图示左肺动脉血流速度增快.结论 应用导管介入治疗直径≥5 mm婴幼儿大型PDA是安全、有效的方法.     

应用Amplatzer封堵器经导管治疗直径≥8mm动脉导管未闭的疗效评价

目的 :应用 Amplatzer封堵器经导管治疗直径≥ 8mm的大型动脉导管未闭 （PDA）并对其疗效进行评价。方法 :全组 5 0例 ,年龄 2 6 .4± 2 3.2 （4.0～ 6 0 .0 ）岁。 PDA最窄处直径为 10 .2± 2 .3（8.0～ 15 .0 ） mm。封堵 10 m in后行侧位降主动脉造影 ,术后 1d及 1月行超声心动图检查 ,观察有无残余分流及 PDA再通。结果 :47例 PDA采用Amplatzer PDA封堵器治疗 ,2例采用 Amplatzer ASD封堵器治疗 ,1例 PDA伴有阻力性肺动脉高压未行介入治疗。术后 10 min降主动脉造影显示 ,19例存在微～少量残余分流 ,30例封堵完全无残余分流。术后 2 4h、术后 1月超声心动图未见残余分流及再通。结论 :应用 Am platzer封堵器治疗直径≥ 8mm的大型动脉导管未闭是一种安全有效的介入方法。     

Amplatzer封堵器经导管治疗动脉导管未闭169例的随访结果

目的 :应用 Amplatzer封堵器经导管治疗动脉导管未闭 （PDA）术后随访。方法 :全组 16 9例。PDA最窄处直径为 4 .7± 3.8（2 .0～ 13.0 ） mm。封堵后 10 min行降主动脉造影 ,术后 2 4 h及 1,3,6月 ,1年行超声心动图检查随访。结果 :16 6例 PDA采用 Amplatzer PDA封堵器治疗 ,3例采用 Am platzer房间隔缺损封堵器治疗。 1例 PDA术中证实伴有阻力性肺动脉高压未行介入治疗。术后 10 m in降主动脉造影示 ,5 4例存在微～少量残余分流 ,114例封堵完全无残余分流。术后 2 4 h13例存在微～少量残余分流 ,余超声心动图未见残余分流及再通。 1例封堵术后 10h并发溶血 ,4 8h后行外科 PDA缝合术。术后 1月超声心动图检查 5例存在少量残余分流 ,术后 3月 4例存在少量残余分流 ,6月及 1年 3例存在少量残余分流 ,最后行 PFM弹簧圈治疗未再见残余分流。无并发症发生。结论 :应用 Am platzer封堵器治疗 PDA是一种安全有效的介入方法     

关于婴幼儿动脉导管未闭介入治疗的临床研究

目的：探讨Amplatzer法介入封堵治疗婴幼儿动脉导管未闭（PDA）的经验，治疗意义，操作技术及安全性。方法：回顾性分析32例婴幼儿PDA患儿资料，患儿年龄≤3岁，平均（13±5．5）月，体重（10．3±4．2）kg；做右心导管，实行封堵术，术后24h，1、3、6、12月复查超声心动图。结果：32例患儿中29例（90．6％）封堵成功，PDA最窄处直径（4．2±2．1）mm。失败者2例为PDA封堵器主动脉侧过大，导致降主动脉局部狭窄、迂曲变形而放弃封堵，1例封堵术后封堵器周围大量残余分流，行外科手术治疗。并发症包括术后残余分流、股动脉搏动减弱及伤口出血等。结论：在严格选择适应证的条件下，介入封堵婴幼儿动脉导管未闭较为安全，可行。     

应用Amplatzer封堵器经导管治疗动脉导管未闭开胸术后再通的疗效评价

目的 :应用 Am platzer封堵器经导管治疗动脉导管未闭 （PDA）开胸术后再通并对其疗效进行评价。方法 :全组10例 ,年龄 11± 8（4～ 32 ）岁。PDA最窄处直径为 4± 4（2～ 13） mm。封堵后 10 m in行侧位降主动脉造影 ,术后 1d及 1月行超声心动图检查 ,观察有无残余分流及 PDA再通。结果 :9例 PDA采用 Am platzer PDA封堵器治疗 ,1例采用 Amplatzer房间隔缺损封堵器治疗。术后 10 m in降主动脉造影显示 ,3例存在微量～少量残余分流 ,7例封堵完全无残余分流。术后 2 4h、术后 1月超声心动图均未见残余分流及再通。结论 :应用 Amplatzer封堵器治疗动脉导管未闭外科术后再通是一种安全有效的介入方法。     

应用Amplatzer封堵器经导管治疗动脉导管未闭并发重度肺动脉高压的疗效评价

目的 :应用 Amplatzer封堵器经导管治疗动脉导管未闭 （PDA）并发重度肺动脉高压 （SPH） ,并对其疗效进行评价。方法 :全组 15例 ,年龄 2 5± 2 2 （5～ 54）岁。PDA最窄处直径为 11± 4（8～ 18） mm。 PDA 8例采用 AmplatzerPDA封堵器治疗 ,7例采用 Amplatzer房间隔缺损封堵器治疗。封堵后 3 0 min行侧位降主动脉造影 ,术后 1d及 1月行超声心动图检查 ,观察有无残余分流及 PDA再通。结果 :14例 （93 ） %封堵后 3 0 min至 1h肺动脉收缩压由 90～ 150 （10 6± 2 7） mm Hg降至 45～ 110 （65± 2 1） mm Hg,肺动脉平均压由 60～ 10 5（82± 2 1） mm Hg降至 2 6～ 65（50± 19） mm Hg。 1例封堵后 3 0 min至 1h肺动脉收缩压无下降 ,反而有轻度上升 ,考虑为阻力性重度肺动脉高压 ,撤出封堵器。 6例主动脉压力有不同程度增高。术后 3 0 min降主动脉造影示 ,5例存在微至少量残余分流 ,10例封堵完全无残余分流。在术后 2 4h2例仍存在微至少量残余分流 ,其中 1例并发溶血 ,48h后行外科 PDA缝合术。其余病例术后 1月超声心动图检查未见残余分流及再通。结论 :应用 Amplatzer封堵器治疗 PDA并发 SPH是一种安全有效的介入方法     

国产封堵器介入治疗巨大动脉导管未闭的临床评价

目的应用国产封堵器经导管治疗巨大动脉导管未闭（PDA）并对其疗效进行评价。方法全组27（男8,女19）例,年龄6～54（24±15）岁,主动脉造影示PDA最窄径为13～28（16±4）mm。封堵后即刻和30min行侧位降主动脉造影,术后2d,1、3、6个月分别行超声心动图及X线平片检查。结果24例成功,3例PDA封堵后判断为有阻力性肺动脉高压,放弃治疗。成功的患者中,14例选用国产PDA封堵器,10例选用国产ASD封堵器。术后即刻降主动脉造影检查示,使用ASD封堵器中,有2例微量残余分流,5例少量残余分流,1例少～中量残余分流;PDA封堵器中,有4例微量残余分流,2例少量残余分流。术后30min,ASD封堵器4例微～少量残余分流,1例仍为少～中量残余分流;PDA封堵器仅2例微量残余分流。1例ASD封堵器治疗术后7h发生溶血,治疗72h溶血无减轻迹象,外科开胸取出封堵器并行PDA结扎术。术后2d,超声心动图示PDA封堵器1例微量残余分流,ASD封堵器5例微量残余分流。随访1～6个月,所有左心内径增大的患者均明显回缩,未发现残余分流和导管再通。结论应用国产封堵器经导管治疗直径≥13mm的PDA是一种安全有效地介入方法。     

房间隔缺损封堵器封堵巨大动脉导管未闭后发生机械性溶血二例

动脉导管未闭(PDA)是一种常见的先天性心脏病,经导管封堵治疗已广泛应用于临床。Amplatzer封堵器可用于封堵各种类型PDA,效果佳、创伤小、安全性高。直径≥10 mm的巨大PDA术后易发生溶血、残余分流、封堵器脱落和封堵器脱位等严重并发症[1]。常规PDA封堵器最大直径为20 mm,若需更大直径的封堵器,多选择房间隔缺损封堵器(ASO)或肌部室间隔封堵器。中南大学湘雅二医院2011年     

婴幼儿大型动脉导管未闭76例介入治疗的护理

目的探讨经导管介入治疗直径≥5mm婴幼儿大型动脉导管未闭（patentductusarteriosus．PDA）的护理方法。方法回顾性分析76例婴幼儿大型PDA（≥5mm）患儿的临床资料,着重分析介入治疗术前准备、术后病情观察,并发症护理措施等。结果本组76例PDA均封堵成功。经过术前、术后的仔细观察和精心的护理,全部患儿随访1个月至1年,无发生与护理及手术有关的并发症。结论严密观察患儿的生命体征、面色、尿色、伤口、足背动脉搏动、下肢皮温及心脏杂音等变化,及时发现病情,做好护理工作,协助医生及时处理等,对保证大型PDA患儿介入治疗成功有重要作用。     

第二代Amplatzer动脉导管未闭封堵器介入治疗小儿先天性心脏病

目的总结第二代Amplatzer动脉导管未闭封堵器(amplatzer duct occluderⅡ,ADO-Ⅱ)介入治疗小儿先天性心脏病的疗效和经验。方法对湖南省儿童医院2014年1月至2015年6月采用ADO-Ⅱ进行封堵的24例先天性心脏病患儿临床资料进行总结。其中动脉导管未闭18例、室间隔缺损(肌部)2例以及冠状动脉瘘4例。术前经临床以及经胸超声心动图筛选,术中心导管造影结合经胸超声心动图及术后即刻和随访,观察术后残余分流、封堵器位置以及并发症。结果 16例动脉导管未闭即刻封堵成功,无残余分流,无并发症;2例动脉导管未闭即刻封堵时有少许残余分流,无其他并发症。3例冠状动脉瘘封堵器无残余分流,1例冠状动脉瘘封堵处术后1个月少许线样分流。2例室间隔缺损均即刻封堵成功,无残余分流,心电图未见明显房室传导阻滞。结论 ADO-Ⅱ封堵器以其操作相对简便、成功率高以及并发症少的优点,在把握适应证的前提下值得临床推广。     

经导管堵闭婴幼儿大型动脉导管未闭(≥4mm)的短中期随访

目的分析经导管封堵婴幼儿大型动脉导管未闭(patent ductus arteriosus,PDA)(≥4 mm)的短中期随访的结果。方法回顾性分析50例大型PDA患儿的疗效、并发症及中期随访结果 ,评价其中期疗效、安全性及影响疗效的因素。结果成功植入封堵器49例(98%),其中46例(92%)应用PDA封堵器,2例(4%)应用肌部室间隔缺损封堵器,1例(2%)应用膜周对称型室间隔缺损封堵器。术后3 d内复查超声心动图:4例(8%)有残余分流;封堵后左心室舒张末内径、左心房内径、左心室射血分数、肺动脉收缩压、三尖瓣反流(tricuspidregurgitation,TR)及二尖瓣反流(mitral regurgitation,MR)均较术前缩小或减轻,差异有统计学意义(P<0.05);封堵后主动脉收缩压及主动脉瓣反流(aortic regurgitation,AR)较术前增加或加重,差异有统计学意义(P<0.01)。出院后完成随访41例,随访率81.6%,中位随访时间6个月(1～57个月)。残余分流率在术后3 d、1个月、6个月分别为8%、4%、2%。术后1～6个月内左心室射血分数较术后3 d有明显改善,差异有统计学意义(P=0.000);术后1年内随访:MR较术前降低,差异有统计学意义(P=0.000);AR及TR与术前比较,差异无统计学意义(P>0.05);术后1年内11例患儿出现左肺动脉血流速度加快(1.5～2.1 m/s),其中9例随访1年以上左肺动脉血流1.5～2.0 m/s,4例随访3～5年左肺动脉血流速度1.5～2 m/s,但左肺动脉至主肺动脉压差均≤20 mm Hg(1 mm Hg=0.133 kPa)。无降主动脉狭窄。结论经导管用封堵器治疗婴幼儿大型PDA(≥4 mm)的短中期疗效确切,安全性好,但对左肺血流速度增快患者需长期随访。     

Use of Amplatzer duct occluder to close severely hypertensive ducts: utility of transient balloon occlusion

BACKGROUND: The dividing line between a patent ductus arteriosus with severe but reversible pulmonary artery hypertension and an Eisenmenger duct remains elusive. Increasing experience with the Amplatzer duct occluder has made non-surgical closure of even large patent ductus arteriosus simple and safe. However, data on the use of this device in severly hypertensive ducti is sparse. METHODS AND RESULTS: There were six patients (2 males, 4 females), wherein transient ductal occlusion was done with an embolectomy balloon catheter. The post-occlusion hemodynamics along with overall clinical and hemodynamic assessment was used to decide the likelihood of benefit of closure and the choice of the device. In four of six patients of patent ductus arteriosus with severe pulmonary artery hypertension (pulmonary vascular resistance index> 8.0 U/m2) the duct was successfully closed using the Amplatzer duct occluder, while in two an Amplatzer ventricular septal defect occluder was used. CONCLUSIONS: Transient balloon occlusion is quite helpful for assessing patients with patent ductus arteriosus with severe pulmonary hypertension, and short-term non-invasive follow-up has shown this strategy to be safe and useful.     

Safety and Feasibility of Transcatheter Closure of Large Patent Ductus Arteriosus Measuring ≥4 mm in Patients Weighing ≤6 kg

Objectives: The study aims to find safety of transcatheter closure of large patent ductus arteriosus (PDA) ≥4 mm in patients weighing ≤6 kg.
Background: Large PDA ≥4 mm in patients ≤6 kg challenge the interventionist due to need for large delivery sheath, kink of delivery sheath, and encroachment of aorta or pulmonary artery (PA) by the device. Many institutions refer them for surgery.
Methods: Preterm neonates and ducts with coarctation were excluded. All other patients were taken for catheter closure. Ducts with roomy ampulla were closed with multiple coils aided by bioptome, and others with Amplatzer duct occluders.
Results: Twenty-eight patients aged 2–18 months (median 5.5 months) and weighing 3.8–6 kg (median 4.7 kg) had large PDA (mean diameter 6.3 ± 2 mm) with hyperkinetic pulmonary hypertension. Four patients had bioptome-aided coil closure. Twenty-two other ducts were closed with devices. Two procedures failed due to sheath kink in one patient and device pulling through a duct in the other patient. Four infants needed blood transfusions. The mean procedural time was 42 ± 20 minutes. On a mean follow-up of 25.5 ± 14.8 months, there were no residual flows and no gradients across aorta or pulmonary artery.
Conclusions: Transcatheter closure of large ducts ≥4 mm might be considered safe and effective in infants weighing ≤6 kg also. Decision on coils versus devices depends on ductal morphology. On midterm follow-up with somatic growth, there was no occurrence of aortic or PA gradients.     

应用国产封堵器治疗儿童大型动脉导管未闭的疗效研究

目的:评价应用国产封堵器经导管治疗儿童大型动脉导管未闭的安全性及有效性。方法:12岁以下大型动脉导管未闭患儿66例,应用国产封堵器经导管进行介入治疗,于术后1、3、6月及每年进行超声心动图等随访,观察有无残余分流及主动脉狭窄等,评估该方法的效果及安全有效性。结果:技术成功率97%。应用目前最大封堵器失败转外科手术1例,由于重度肺动脉高压,试封堵后肺动脉压力无明显改善而放弃治疗1例。手术即刻残余分流率为23%,随访观察1月后为3%,6月后所有64例患儿均无残余分流。结论:国产封堵器经导管治疗儿童大型动脉导管未闭安全可行。     

Safety and feasibility of transcatheter closure of large patent ductus arteriosus measuring >or=4 mm in patients weighing

Kothandam Sivakumar  Edwin Francis  Prasad Krishnan 《Journal of interventional cardiology》2008,21(2):196-203

Patent ductus arteriosus closure using an Amplatzer? ventricular septal defect closure device

The ductus arteriosus originates from the persistence of the distal portion of the left sixth aortic arch. It connects the descending aorta (immediately distal to the left subclavian artery) to the roof of the main pulmonary artery, near the origin of the left pulmonary artery. Persistence of the duct beyond 48 h after birth is abnormal and results in patent ductus arteriosus (PDA). PDA is rare in adults because it is usually discovered and treated in childhood. Mechanical closure remains the definitive therapy because the patency of ductus arteriosus may lead to multiple complications, depending on the size and flow through the ductus. PDA closure is indicated in patients with symptoms and evidence of left heart enlargement, and in patients with elevated pulmonary pressures when reversal is possible. Transcatheter closure is the preferred technique in adults because it avoids sternotomy, reduces the length of hospital stay and is associated with fewer complications compared with surgery. First demonstrated in 1967, both the technique and the occluder devices used have since evolved. However, designing an ideal PDA occluder has been a challenge due to the variability in size, shape and orientation of PDAs. The present article describes a case involving a 35-year-old woman who presented to the Center for Advanced Heart Failure (Houston, USA) with congestive heart failure due to a large PDA, which was successfully occluded using an Amplatzer (St Jude Medical, USA) muscular ventricular septal defect closure device. The wider waist and dual-retention discs of these ventricular septal defect closure devices may be important factors to consider in the future development of devices for the occlusion of large PDAs.     

房间隔缺损并发畸形的介入治疗

目的 :评价同期应用介入治疗房间隔缺损 （ASD）及其并发心脏其它畸形的可行性和治疗效果。方法 :全组 7例 ,年龄 2～ 6 5 （34± 2 8）岁。经临床、心电图、X线及超声心动图诊断为 ASD并发其他心脏畸形 ,其中 3例为肺动脉瓣狭窄 ,2例为二尖瓣狭窄 （L utembacher综合征 ） ,2例为动脉导管未闭 （PDA ）。应用 Amplatzer封堵器经导管关闭ASD前 ,先纠正其它畸形 （包括瓣膜成形术及 PDA封堵术 ）。术后 3d,1～ 6月分别行经胸超声心动图 （TTE）、心电图、X线检查评价治疗效果。结果 :7例同期介入治疗均获得成功 ,术中未发生任何重要并发症。术后 3d,1～ 6月TTE显示房间隔无残余分流。并发肺动脉瓣狭窄患者 ,术后即刻跨肺动脉瓣压差得到满意的下降 ;L utembacher综合征患者 ,二尖瓣瓣口面积分别由术前 1.0 ,1.2 cm2增加到术后 1.9,2 .0 cm2 ,左房平均压分别由 2 9,2 6 m m Hg（1mm Hg=0 .133k Pa）降至 8,7m m Hg;并发 PDA患者 ,应用 Amplatzer封堵器 PDA关闭术后 10 min降主动脉侧位造影 ,无残余分流。术后 6月 X线检查显示肺血减少 ,心脏房、室缩小。结论 :同期介入治疗 ASD并发某些心脏畸形是一种有效、安全、简便可行的方法。     

Transcatheter closure of a large patent ductus arteriosus with the clamshell septal umbrella

In 14 patients undergoing transcatheter closure of a large (greater than 4 mm diameter) patent ductus arteriosus, occlusion was attempted with use of the Bard Clamshell septal umbrella. Patient age ranged from 0.7 to 30.4 years. Isolated patent ductus arteriosus was present in 11 patients; 3 had additional congenital heart lesions. Moderate or severe pulmonary hypertension was present in four patients. The diameter of the patent ductus arteriosus ranged from 4.5 to 14 mm, as determined by contrast injection through an 11F sheath or by balloon sizing; it appeared larger by this method than by the standard angiographic method. All 14 patent ductus arteriosi were successfully closed. Prior embolization of a Rashkind umbrella was the reason for using a Clamshell device in three patients; one additional embolization of a Clamshell device occurred. All errant devices were retrieved at cardiac catheterization, without associated hemodynamic instability. No other complications occurred. Among the 14 patients, 11 had complete ductal closure by Doppler color flow mapping at last follow-up and 3 had trivial residual flow. All four patients having associated complex lesions or pulmonary hypertension, or both, had symptomatic improvement after the procedure, although one child (with Shone's anomaly) died 3 months later. The Clamshell device provides stable and effective closure of a large patent ductus arteriosus, and allows transcatheter closure to be offered to some patients who were previously considered unsuitable for this procedure.     

Percutaneous catheter closure of the ductus arteriosus in children and young adults

The double-disk occluding device suitable for use in infants and children with patent ductus arteriosus, developed by Rashkind and Mullins, has been available to this institution since December 1987 on an investigational basis. Results of 43 nonsurgical ductal closure attempts using this device in children and young adults between December 1987 and October 1988 are presented. Successful implantation was achieved in 42 patients (98%). In 25 patients a residual shunt was seen on angiography immediately after implantation. In 12 patients a residual ductal shunt was detected by Doppler 24 hours after implantation; 6-week follow-up studies showed a small residual shunt in only 3 patients. After a second occluder device was implanted in 2 of these patients, complete closure of the patient ductus arteriosus was achieved. In 1 patient, early in the series, the occluder device embolized to the left pulmonary artery, necessitating surgical removal at the time of ductus division. This event was the only serious complication; there were no deaths.     

Successful closure of a large PDA with an Amplazter septal occluder in a child with heart failure and pulmonary hypertension--a case report

Transcatheter methods for closure of patent ductus arteriosus (PDA) have been known as an effective technique for many years. The devices designed for interventional closure of PDA, coexisting with elevated pulmonary artery pressure are still far from ideal and there is a significant risk of embolisation into the aorta. We present a case of a 14-year-old girl with a large PDA, pulmonary hypertension and congestive heart failure. She underwent successful PDA closure with an Amplatzer atrial septal occluder (ASO), a device originally designed to close an atrial septal defect.